Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryBluecross Idaho Encelto Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentBluecross IdahoPolicy MP 5.01.679

    Encelto for idiopathic macular telangiectasia type 2

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy MP 5.01.679 alerts

    Get alerted when Policy MP 5.01.679 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage of Encelto (revakinagene taroretcel-lwey), a surgically implanted gene-based therapy, for adults with idiopathic macular telangiectasia type 2. It defines initial-treatment medical-necessity criteria and circumstances in which repeat treatment or other requests are investigational or not medically necessary.

    Policy Summary
    PayerBluecross Idaho
    PolicyEncelto for idiopathic macular telangiectasia type 2
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateNovember 1, 2026
    Last ReviewJul 30, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming all initial-treatment medical-necessity criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was added to the medical policy library as a new policy effective November 1, 2026.

    21+Minimum age for initial treatment
    0.16-2.00 mm²Required ellipsoid-zone area
    54+ lettersRequired BCVA
    1 implant/eyeTreatment limit

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 monthsRecent-treatment lookback

    Medical Necessity and Exclusions

    Initial Treatment

    Encelto may be considered medically necessary for initial treatment when all of the following are met:

    Initial treatment

    • Age: The individual is 21 years of age or older.>= 21 years
    • Diagnosis and fluorescein leakage: The individual has a diagnosis of idiopathic MacTel type 2 in at least one eye with evidence of fluorescein leakage typical of MacTel.
    • ONE or more characteristic retinal findings

      • Hyperpigmentation outside a 500-micron radius from the center of the fovea.
      • Retinal opacification.
      • Crystalline deposits.
      • Right-angle vessels.
      • Inner/outer lamellar cavities.
    • SD-OCT findings: The individual has an inner segment–outer segment junction line (IS/OS) photoreceptor break in the affected eye or eyes and an ellipsoid-zone (EZ) area between 0.16 mm² and 2.00 mm², measured by spectral-domain optical coherence tomography (SD-OCT).EZ 0.16-2.00 mm²
    • Best corrected visual acuity: The individual demonstrates a best corrected visual acuity (BCVA) score of 54 letters or better, or Snellen 20/80 or better.BCVA >= 54 letters or Snellen 20/80 or better

    Continuation, Exclusions, and Other Indications

    Repeat treatment is investigational, and requests are not medically necessary under the following circumstances:

    Noncovered or investigational circumstances

    • Repeat treatment: The individual has previously received an Encelto implant in the affected eye. Repeat treatment is considered investigational because safety and efficacy beyond one implant per eye have not been studied.More than 1 implant per eye

      Investigational.

    • Neovascularization: The individual has exudative macular neovascularization, intraretinal neovascularization, or subretinal neovascularization (SRNV).
    • Recent intravitreal therapy: The individual has had intravitreal steroid therapy or vascular endothelial growth factor inhibitors (anti-VEGFs) within the previous 3 months.Within previous 3 months

    Repeat treatment with Encelto in an eye that previously received an Encelto implant is considered investigational, because safety and efficacy beyond one implant per eye have not been studied.

    Requests are not medically necessary when the individual has exudative macular neovascularization, intraretinal neovascularization, or subretinal neovascularization (SRNV).

    Requests are not medically necessary when the individual has received intravitreal steroid therapy or vascular endothelial growth factor inhibitors (anti-VEGFs) within the previous 3 months.

    Requests are not medically necessary when the individual has an active ocular and/or peri-ocular infection.

    Requests are not medically necessary when the individual is pregnant or plans to become pregnant.

    Encelto requests are not medically necessary when the initial-treatment criteria are not met or when the request is for any other indication.

    Billing Codes and Clinical Parameters

    HCPCSHCPCS
    J3403Revakinage taroretcel-lwey, per implant
    CPTCPT
    No codes listed
    ICD-10-CMICD-10
    H35.071Retinal telangiectasis, right eye
    H35.072Retinal telangiectasis, left eye
    H35.073Retinal telangiectasis, bilateral
    H35.079Retinal telangiectasis, unspecified eye
    ICD-10-PCSICD-10
    No codes listed
    Age
    RequirementIndividual is 21 years of age or older
    Minimum age21 years
    ApplicationRequired for initial Encelto treatment
    Retinal finding
    DiagnosisMacTel type 2 in at least one eye
    LeakageFluorescein leakage typical of MacTel
    Required finding

    Authorization and Documentation Requirements

    Prior Authorization

    Initial-Treatment Authorization Required

    Prior authorization is required for initial treatment with Encelto (revakinagene taroretcel-lwey). The authorization request must establish that all initial-treatment medical-necessity criteria are met, including the required diagnosis, retinal findings, imaging, and visual-acuity thresholds.

    • Submit documentation supporting every applicable initial-treatment criterion before treatment is administered.
    Documentation Required

    Diagnosis and Characteristic Retinal Findings

    Document that the individual is at least 21 years of age and has idiopathic macular telangiectasia type 2 (MacTel type 2) in at least one eye, with fluorescein leakage typical of MacTel and at least one characteristic retinal finding.

    • Hyperpigmentation outside a 500-micron radius from the center of the fovea
    • Retinal opacification

    Condition Overview

    MacTel type 2 is a usually bilateral macular disorder involving neurodegeneration, retinal vascular changes or proliferation, and leakage. The condition is progressive and may lead to progressive central vision loss.

    Key Terms

    Encelto (revakinagene taroretcel-lwey)
    Therapy typeCell-based gene therapy
    Delivery mechanismGenetically modified cells are encapsulated in a semipermeable hollow-fiber membrane and implanted intravitreally
    Therapeutic releaseThe implanted cells release recombinant human ciliary neurotrophic factor (rhCNTF) to the retina
    Treatment approachThe capsule is surgically placed into the vitreous fluid and anchored to the sclera as a one-time treatment
    MacTel type 2
    Full termIdiopathic macular telangiectasia type 2
    Pattern
    Policy Summary
    PayerBluecross Idaho
    PolicyEncelto for idiopathic macular telangiectasia type 2
    Policy CodePolicy N/A
    Change TypeNew policy
    Effective DateNovember 1, 2026
    Last ReviewJul 30, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming all initial-treatment medical-necessity criteria are met.
    SourceLink
    On This Page
    Medical Necessity and ExclusionsBilling Codes and Clinical ParametersAuthorization and Documentation RequirementsCondition OverviewKey Terms
  1. Active infection: The individual has an active ocular and/or peri-ocular infection.
  2. Pregnancy: The individual is pregnant or plans to become pregnant.
  3. Other indication or unmet criteria: The initial-treatment criteria are not met, or the request is for any other indication.

    Not medically necessary.

  4. At least one of the following: hyperpigmentation outside a 500-micron radius from the foveal center; retinal opacification; crystalline deposits; right-angle vessels; or inner/outer lamellar cavities
    Ellipsoid-zone area
    MeasurementEllipsoid-zone (EZ) area
    ModalitySpectral-domain optical coherence tomography (SD-OCT)
    Required range0.16 mm² to 2.00 mm²
    Best corrected visual acuity
    MeasureBest corrected visual acuity (BCVA)
    Letter score54 letters or better
    Snellen equivalent20/80 or better
    Recent intravitreal treatment lookback
    Restricted treatment historyIntravitreal steroid therapy or vascular endothelial growth factor inhibitors (anti-VEGFs)
    Lookback periodPrevious 3 months
    Initial-treatment requirementNo listed intravitreal steroid or anti-VEGF treatment within the previous 3 months
  5. Crystalline deposits
  6. Right-angle vessels
  7. Inner/outer lamellar cavities
  8. Identify the affected eye or eyes.
  9. Documentation Required

    Imaging and Visual-Acuity Documentation

    Submit imaging and visual-acuity documentation for the affected eye or eyes. The record must show an inner segment–outer segment junction line (IS/OS) photoreceptor break and an ellipsoid zone (EZ) area within the required range on spectral-domain optical coherence tomography (SD-OCT), together with qualifying best-corrected visual acuity.

    • EZ area must measure between 0.16 mm² and 2.00 mm² by SD-OCT.
    • BCVA must be 54 letters or better, or Snellen 20/80 or better.

    Unsupported block type: documentation

    Denial Risk

    Initial Criteria Not Met

    Initial treatment may be denied when any required medical-necessity criterion is not satisfied or cannot be documented. This includes the age, MacTel type 2 diagnosis, characteristic fluorescein leakage or retinal findings, SD-OCT imaging, ellipsoid-zone measurement, IS/OS photoreceptor break, or visual-acuity requirements.

    • The individual must be at least 21 years of age.
    • MacTel type 2 must be documented in at least one eye with typical fluorescein leakage and at least one characteristic retinal finding.
    • The affected eye or eyes must meet the required SD-OCT and EZ-area criteria, and BCVA must be 54 letters or better or Snellen 20/80 or better.
    Denial Risk

    Excluded Clinical Circumstances

    Repeat treatment with Encelto for any indication is investigational because safety and efficacy beyond one implant per eye have not been studied. Requests are not medically necessary when a listed exclusion applies or when the initial criteria are not met; coverage is also not medically necessary for all other indications.

    • A prior Encelto implant in the affected eye makes repeat treatment investigational.
    • Exclusions include exudative macular neovascularization, intraretinal neovascularization or subretinal neovascularization (SRNV); intravitreal steroid or anti-VEGF therapy within the previous 3 months; active ocular or peri-ocular infection; and pregnancy or plans to become pregnant.
    Generally bilateral, although each eye may be affected differently
    Associated retinal changesRetinal degeneration, vascular proliferation, dilation, and leakage
    Clinical progressionProgressive central vision loss may occur
    IS/OS photoreceptor break
    Anatomical structureInner segment–outer segment junction line of the photoreceptors
    Imaging findingPhotoreceptor break
    Required locationAffected eye or eyes
    EZ
    MeaningEllipsoid-zone area
    Measurement methodSpectral-domain optical coherence tomography (SD-OCT)
    Initial-treatment range0.16 mm² to 2.00 mm²